Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Curr Cardiol Rep. 2020 Jun 30;22(8):75. doi: 10.1007/s11886-020-01307-z.
Erdheim-Chester disease (ECD) is a very rare neoplasm of the non-Langerhans cell histiocytes. Pericardial involvement is uncommon, and we aim to review the current knowledge on the epidemiology, clinical manifestations, and management of recurrent pericarditis due to ECD. We also aim to raise awareness of the importance of considering ECD as a differential diagnosis for recurrent pericarditis in the appropriate clinical settings.
The prevalence of pericardial involvement in ECD is estimated to be 40% and is getting more recognized recently. Up to 68% of patients carry the BRAFV600E mutation, and targeted treatment with vemurafenib, an inhibitor of BRAF kinase, showed an excellent response in those who carry this mutation. Pericardial disease appears to be the most common cardiac presentation (in 80% of cases). Although pericardial involvement is frequently asymptomatic, patients with ECD can present with typical pericarditis chest pain and signs of right heart failure if constriction is present. The diagnosis of ECD requires a biopsy of the pericardium or another affected organ. If BRAFV600E mutation is absent, limited data exist, and many medications have been tried, like interferon alfa, anakinra, and infliximab.
Erdheim-Chester 病(ECD)是一种罕见的非朗格汉斯细胞组织细胞肿瘤。心包受累并不常见,我们旨在回顾 ECD 引起复发性心包炎的流行病学、临床表现和治疗的现有知识。我们还旨在提高人们的认识,即在适当的临床环境中,应将 ECD 作为复发性心包炎的鉴别诊断。
ECD 心包受累的患病率估计为 40%,最近越来越受到关注。多达 68%的患者携带 BRAFV600E 突变,针对携带该突变的 BRAF 激酶抑制剂 vemurafenib 的靶向治疗显示出极好的反应。心包疾病似乎是最常见的心脏表现(占 80%的病例)。尽管心包受累通常无症状,但如果存在缩窄,ECD 患者可出现典型的心包炎胸痛和右心衰竭体征。ECD 的诊断需要心包或其他受累器官的活检。如果不存在 BRAFV600E 突变,则数据有限,并且已经尝试了许多药物,如干扰素 alfa、anakinra 和 infliximab。